Clinical research - Press Releases

Date	Title	Company
14-Dec-2022	Conference Co-chairs from Merck & AstraZeneca invitation to join 3D Cell Culture	SAE Media Group
13-Dec-2022	Curebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic Studies	Curebase
13-Dec-2022	CluePoints Appoints Andy Cooper as New Chief Executive Officer	CluePoints
13-Dec-2022	1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors	1ST Biotherapeutics, Inc.
08-Dec-2022	PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations	PHASTAR
08-Dec-2022	MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients	MetrioPharm AG
07-Dec-2022	PHASTAR Launches Pro-Bono Scheme for Charities	Phastar
07-Dec-2022	The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis	UCB
07-Dec-2022	Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022	Enterome
06-Dec-2022	MHRA approves Adtralza®▼(tralokinumab) for the treatment of adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy	LEO Pharma
06-Dec-2022	Pumas-AI Hires Dr. Salim Bouchene and Expands Consulting Practice in Europe	Pumas-AI
06-Dec-2022	Platelet Services celebrates record year	Platelet Services
06-Dec-2022	Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study	Mainz Biomed
06-Dec-2022	ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma	ImaginAb
06-Dec-2022	Olympus to Join Government Project to Verify Dissemination of Endoscopic AI Diagnosis in Vietnam	OLYMPUS
02-Dec-2022	Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s	Eisai
02-Dec-2022	BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia	BioXcel Therapeutics
02-Dec-2022	Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022	Achilles Therapeutics
02-Dec-2022	Diphtheria outbreak – the Government must drop its complacency and step-up testing, warns expert	Diphtheria outbreak – the Government must drop its complacency and step-up testing, warns expert
01-Dec-2022	International Society of Pharmacometrics Names Pumas-AI Co-Founder Dr. Vijay Ivaturi as President-Elect	Pumas-AI